# Clinical Trials Data ALK - Document 20

# Clinical Relevance of ROS (V-ros UR2 Sarcoma Virus Oncogene Homolog) Aberrations in Solid Tumours

## Clinical Trial: https://clinicaltrials.gov/study/NCT01596374

"eligibilityCriteria": "Inclusion Criteria:\n\n- Patients with cancer",  
 "healthyVolunteers": false,  
 "sex": "ALL",  
 "minimumAge": "21 Years",  
"stdAges": [  
"ADULT",  
"OLDER\_ADULT"  
],  
 "studyPopulation": "Department of Pathology, NUH Tissue Repository, The samples collected for the study are leftover clinical samples and the patients have consented for their samples to be used for research.",

Question:  
Based on the following clinical trial information, would a patient with a ALK gene mutation be eligible for the clinical trial?

Answer:  
Based on the provided information, having an ALK gene mutation is not mentioned as either an inclusion or exclusion criterion. The only inclusion criterion listed is having cancer. Therefore, \*\*if the patient with the ALK gene mutation has cancer and is 21 years or older, they \*might\* be eligible\*\*. However, more information is needed about specific inclusion/exclusion criteria related to cancer type and other factors. The fact that the study uses leftover clinical samples suggests it may focus on specific cancer types, and the ALK mutation is relevant primarily in certain cancers (like lung cancer). It's crucial to contact the study organizers to determine definitive eligibility.